Samuel N. Hazen - 03 Feb 2026 Form 4 Insider Report for HCA Healthcare, Inc. (HCA)

Signature
/s/ Kevin A. Ball, Attorney-in-Fact
Issuer symbol
HCA
Transactions as of
03 Feb 2026
Net transactions value
-$21,483,275
Form type
4
Filing time
05 Feb 2026, 18:33:00 UTC
Previous filing
02 Feb 2026
Next filing
12 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
HAZEN SAMUEL N CEO, Director ONE PARK PLAZA, NASHVILLE /s/ Kevin A. Ball, Attorney-in-Fact 05 Feb 2026 0001216838

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HCA Common Stock Sale $7,401,386 -14,716 -20% $502.95 60,437 03 Feb 2026 Direct F1
transaction HCA Common Stock Sale $2,511,757 -5,002 -8.3% $502.15 55,435 03 Feb 2026 Direct F2
transaction HCA Common Stock Sale $3,702,626 -7,395 -13% $500.69 48,040 03 Feb 2026 Direct F3
transaction HCA Common Stock Sale $3,094,609 -6,189 -13% $500.02 41,851 03 Feb 2026 Direct F4
transaction HCA Common Stock Sale $2,574,794 -5,162 -12% $498.80 36,689 03 Feb 2026 Direct F5
transaction HCA Common Stock Sale $2,138,442 -4,293 -12% $498.12 32,396 03 Feb 2026 Direct F6
transaction HCA Common Stock Sale $59,661 -120 -0.37% $497.18 32,276 03 Feb 2026 Direct F7
transaction HCA Common Stock Other $520,776 -1,045 -3.2% $498.35 31,231 04 Feb 2026 Direct F8
transaction HCA Common Stock Other $520,776 +1,045 +7% $498.35 16,024 04 Feb 2026 By HD Trust F8
holding HCA Common Stock 16,731 03 Feb 2026 By 2023 GST Trust
holding HCA Common Stock 93,088 03 Feb 2026 By 2023 Trust
holding HCA Common Stock 178,289 03 Feb 2026 By 2024 GRAT
holding HCA Common Stock 200,000 03 Feb 2026 By 2025 GRAT
holding HCA Common Stock 813,320 03 Feb 2026 By LP
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.49 to $503.485, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $501.485 to $502.455, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $500.44 to $501.425, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $499.47 to $500.425, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $498.41 to $499.395, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $497.49 to $498.385, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $497.10 to $497.38, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 Pursuant to a power of substitution, on February 4, 2026, the Reporting Person transferred 1,045 shares of common stock of the Issuer to a trust in exchange for assets of equal value. The transfer was made at a price per share equal to $498.35 (the average of the high and low prices of shares of common stock of the Issuer on February 4, 2026). The transfer did not change the total number of shares of common stock of the Issuer of which the Reporting Person may be deemed to have beneficial ownership. The Reporting Person believes that the transfer of shares to the trust constitutes a change in form of beneficial ownership of such shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934.